Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Trehalose. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | TYR | P14679 | 1/20 | 0.51 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.50 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.50 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.50 |
| ▸ | GJA1 | P17302 | 1/20 | 0.49 |
| ▸ | GJB2 | P29033 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.48 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trehalose SCHEMBL7079380 | 1.00 | MAPT (0.56) | MAPTMEN1KMT2APTPN1L3MBTL1 | |
| Trehalose SCHEMBL166078 | 1.00 | MAPT (0.56) | MAPTMEN1KMT2APTPN1L3MBTL1 | |
| Trehalose SCHEMBL15360972 | 1.00 | MAPT (0.56) | MAPTMEN1KMT2APTPN1L3MBTL1 | |
| Trehalose SCHEMBL1053867 | 1.00 | MAPT (0.56) | MAPTMEN1KMT2APTPN1L3MBTL1 | |
| Trehalose SCHEMBL6827933 | 1.00 | MAPT (0.56) | MAPTMEN1KMT2APTPN1L3MBTL1 | |
| Trehalose SCHEMBL23029503 | 0.98 | MEN1 (0.57) | MAPTMEN1KMT2APTPN1L3MBTL1 | |
| Trehalose SCHEMBL13465987 | 0.98 | MEN1 (0.57) | MAPTMEN1KMT2APTPN1L3MBTL1 | |
| Trehalose SCHEMBL17072366 | 0.98 | MEN1 (0.57) | MAPTMEN1KMT2APTPN1L3MBTL1 | |
| Trehalose SCHEMBL14472517 | 0.98 | MEN1 (0.57) | MAPTMEN1KMT2APTPN1L3MBTL1 | |
| Trehalose SCHEMBL670041 | 0.98 | MEN1 (0.57) | MAPTMEN1KMT2APTPN1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 358 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230055555-A1 | METHOD FOR PREPARING PEPTIDE EMULSION FORMULATION | Sumitomo Pharma Co., Ltd. (JP) | 2023-02-23 | — | — | US | claimed |
| EP-4074332-A1 | METHOD FOR PREPARING PEPTIDE EMULSION FORMULATION | Sumitomo Pharma Co., Ltd. (JP) | 2022-10-19 | — | — | EP | claimed |
| CN-106687129-B | Pharmaceutical composition for injection | 大日本住友制药株式会社 | 2021-07-20 | — | — | CN | claimed |
| WO-2021117771-A1 | METHOD FOR PREPARING PEPTIDE EMULSION FORMULATION | 大日本住友製薬株式会社 | 2021-06-17 | — | — | WO | claimed |
| US-20210128741-A1 | ANTIBODY-DRUG CONJUGATE PREPARATION AND LYOPHILIZATION FOR SAME | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-05-06 | — | — | US | claimed |
| CN-112566635-A | Granular composition and process for producing the same | 日本脏器制药株式会社 | 2021-03-26 | — | — | CN | claimed |
| US-20200299398-A1 | TREATMENT OF CD20-POSITIVE B-CELL LYMPHOMA WITH OBITUZUMAB | GENENTECH, INC. | 2020-09-24 | — | — | US | claimed |
| EP-3697818-A2 | A PHARMACEUTICAL COMPOSITION | H. Hoffnabb-La Roche Ag (CH) | 2020-08-26 | — | — | EP | claimed |
| EP-3673918-A1 | ANTIBODY-DRUG CONJUGATE PREPARATION AND LYOPHILIZATION FOR SAME | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-07-01 | — | — | EP | claimed |
| CN-111212854-A | Treatment of CD20 positive B cell lymphoma with obinmentuzumab | 豪夫迈·罗氏有限公司 | 2020-05-29 | — | — | CN | claimed |
| US-10471136-B2 | Pharmaceutical composition for injection | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-11-12 | — | — | US | claimed |
| US-20180344831-A1 | PHARMACEUTICAL COMPOSITION FOR INJECTION | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-12-06 | — | — | US | claimed |
| EP-3199175-A1 | PHARMACEUTICAL COMPOSITION FOR INJECTION | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2017-08-02 | — | — | EP | claimed |
| CN-106687129-A | Pharmaceutical composition for injection | 大日本住友制药株式会社 | 2017-05-17 | — | — | CN | claimed |
| EP-1094092-B1 | Thermoplastic shaped-body of trehalose, process and uses thereof | HAYASHIBARA BIOCHEM LAB (JP) | 2006-07-26 | — | — | EP | claimed |
| US-5919668-A | NON-REDUCING SACCHARIDE HAVING A TREHALOSE STRUCTURE IN WHICH AT LEAST ONE MOLECULE OF GLUCOSE IS ATTACHED TO EACH OF THE GLUCOSE MOLECULES MAKING UP TREHALOSE; EFFICIENT PRODUCTION OF SWEETENER USED IN PHARMACEUTICALS, FOOD, COSMETICS | KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) | 1999-07-06 | — | — | US | claimed |
| US-5908767-A | CULTURING MICROORGANISMS CAPABLE OF FORMING AN ENZYME; REDUCTION OF STARCH HYDROLYZATE | KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) | 1999-06-01 | — | — | US | claimed |
| US-5677442-A | CRYSTALLIZING FROM CONCENTRATED AQUEOUS SOLUTION | KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) | 1997-10-14 | — | — | US | claimed |
| EP-0691344-A1 | Purification of trehalose | KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) | 1996-01-10 | — | — | EP | claimed |
| EP-0691407-A1 | Non-reducing saccharide and its production and use | KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) | 1996-01-10 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210128741-A1 | ANTIBODY-DRUG CONJUGATE PREPARATION AND LYOPHILIZATION FOR SAME | TREH, CERT1, FUT4 | MEN1 862/4885MAPT 71/4885KMT2A 4040/4885 |
| US-10471136-B2 | Pharmaceutical composition for injection | IAPP, CHAMP1, PTMS | MEN1 1851/4885MAPT 600/4885KMT2A 4721/4885 |
| US-20230055555-A1 | METHOD FOR PREPARING PEPTIDE EMULSION FORMULATION | VIP, IWS1, WFS1 | MEN1 1230/4885MAPT 3849/4885KMT2A 2617/4885 |
| US-20180344831-A1 | PHARMACEUTICAL COMPOSITION FOR INJECTION | IAPP, CHAMP1, PTMS | MEN1 1851/4885MAPT 600/4885KMT2A 4721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.